AEON Biopharma (AEON) Gets FDA Feedback Enabling Streamlined ABP-450 Path

AEON received FDA Type 2b meeting minutes indicating prior head-to-head ABP-450 vs BOTOX studies may be used as supportive evidence, and plans an IND in Q4 2026 for a CMAP PD study while deferring a comparative efficacy study pending totality-of-evidence.Material DetailsContext by AI AnalystThis is…